Creation of Mo/Tc@C60 and Au@C60 and molecular-dynamics simulations

The formation of middle- and/or high-weight atom (Mo, Au)-incorporated fullerenes was investigated using radionuclides produced by nuclear reactions. From the trace radioactivities of ⁹⁹Mo/⁹⁹mTc or ¹⁹⁴Au after high-performance liquid chromatography, it was found that the formation of endohedral and/or heterofullerene fullerenes in ⁹⁹Mo/⁹⁹mTc and ¹⁹⁴Au atoms could occur by a recoil process following the nuclear reactions. Furthermore, the ⁹⁹mTc (and ¹⁹⁴Au) atoms recoiled against β-decay remained present inside these cages. To confirm the produced materials experimentally, ab initio molecular dynamics (MD) simulations based on an all-electron mixed-basis approach were performed. The possibility of the formation of endohedral fullerenes containing Mo/Tc and Au atoms is verified; here, the formation of heterofullerenes is excluded by MD simulations. These findings suggest that radionuclides stably encapsulated by fullerenes could potentially play a valuable role in diagnostic nuclear medicine

Poly[[dodeca­aqua­(μ4-benzene-1,4-dicarboxyl­ato)(μ2-4,4′-bipyridine-κ2 N:N′)dicerium(III)] bis­(benzene-1,4-dicarboxyl­ate)]

The asymmetric unit of the title compound, {[Ce2(C8H4O4)(C10H8N2)(H2O)12](C8H4O4)2}n, consists of half a CeIII cation, a quarter of a coordinated benzene-1,4-dicarboxyl­ate (bdc2−) dianion, a quarter of a 4,4′-bipyridine (bpy) mol­ecule, three water mol­ecules and a half of an uncoordinated benzene-1,4-dicarboxyl­ate dianion. The CeIII ion is located on a twofold rotation axis and exhibits a distorted trigonal prism square-face tricapped coordination geometry. The coordinated and uncoordinated bdc2− ions and the bpy mol­ecule lie about special positions of site symmetries 2/m, m and 2/m, respectively. The CeIII ions are bridged by the bdc2− and bpy ligands, giving a sheet structure parallel to the ac plane. The uncoordinated bdc2− dianion exists between the sheets and links the sheets by inter­molecular O—H⋯O hydrogen bonds between the uncoordinated bdc2− and coordinated water mol­ecules. A π–π stacking inter­action between the uncoordinated bdc2− dianion and the bpy ligand [centroid–centroid distance = 3.750 (4) Å] is also observed

Algebraic Correlation Function and Anomalous Diffusion in the HMF model

In the quasi-stationary states of the Hamiltonian Mean-Field model, we numerically compute correlation functions of momenta and diffusion of angles with homogeneous initial conditions. This is an example, in a N-body Hamiltonian system, of anomalous transport properties characterized by non exponential relaxations and long-range temporal correlations. Kinetic theory predicts a striking transition between weak anomalous diffusion and strong anomalous diffusion. The numerical results are in excellent agreement with the quantitative predictions of the anomalous transport exponents. Noteworthy, also at statistical equilibrium, the system exhibits long-range temporal correlations: the correlation function is inversely proportional to time with a logarithmic correction instead of the usually expected exponential decay, leading to weak anomalous transport properties

SuperNova, a monomeric photosensitizing fluorescent protein for chromophore-assisted light inactivation

Takemoto, K., Matsuda, T., Sakai, N. et al. SuperNova, a monomeric photosensitizing fluorescent protein for chromophore-assisted light inactivation. Sci Rep 3, 2629 (2013). https://doi.org/10.1038/srep02629

Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts

The bone morphogenetic protein (BMP) and Wnt signaling pathways both contribute essential roles in regulating bone mass. However, the molecular interactions between these pathways in osteoblasts are poorly understood. We recently reported that osteoblast-targeted conditional knockout (cKO) of BMP receptor type IA (BMPRIA) resulted in increased bone mass during embryonic development, where diminished expression of Sost as a downstream effector of BMPRIA resulted in increased Wnt/Β-catenin signaling. Here, we report that Bmpr1a cKO mice exhibit increased bone mass during weanling stages, again with evidence of enhanced Wnt/Β-catenin signaling as assessed by Wnt reporter TOPGAL mice and TOPFLASH luciferase. Consistent with negative regulation of the Wnt pathway by BMPRIA signaling, treatment of osteoblasts with dorsomorphin, an inhibitor of Smad-dependent BMP signaling, enhanced Wnt signaling. In addition to Sost , Wnt inhibitor Dkk1 also was downregulated in cKO bone. Expression levels of Dkk1 and Sost were upregulated by BMP2 treatment and downregulated by Noggin. Moreover, expression of a constitutively active Bmpr1a transgene in mice resulted in the upregulation of both Dkk1 and Sost and partially rescued the Bmpr1a cKO bone phenotype. These effectors are differentially regulated by mitogen-activated protein kinase (MAPK) p38 because pretreatment of osteoblasts with SB202190 blocked BMP2-induced Dkk1 expression but not Sost . These results demonstrate that BMPRIA in osteoblasts negatively regulates endogenous bone mass and Wnt/Β-catenin signaling and that this regulation may be mediated by the activities of Sost and Dkk1 . This study highlights several interactions between BMP and Wnt signaling cascades in osteoblasts that may be amenable to therapeutic intervention for the modification of bone mass density. © 2010 American Society for Bone and Mineral ResearchPeer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/65056/1/90806_ftp.pd

Recent Results from LHD Experiment with Emphasis on Relation to Theory from Experimentalist’s View

he Large Helical Device (LHD) has been extending an operational regime of net-current free plasmas towardsthe fusion relevant condition with taking advantage of a net current-free heliotron concept and employing a superconducting coil system. Heating capability has exceeded 10 MW and the central ion and electron temperatureshave reached 7 and 10 keV, respectively. The maximum value of β and pulse length have been extended to 3.2% and 150 s, respectively. Many encouraging physical findings have been obtained. Topics from recent experiments, which should be emphasized from the aspect of theoretical approaches, are reviewed. Those are (1) Prominent features in the inward shifted configuration, i.e., mitigation of an ideal interchange mode in the configuration with magnetic hill, and confinement improvement due to suppression of both anomalous and neoclassical transport, (2) Demonstration ofbifurcation of radial electric field and associated formation of an internal transport barrier, and (3) Dynamics of magnetic islands and clarification of the role of separatrix

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049